Phase III trial of first-line infigratinib vs gemcitabine/cisplatin in FGFR2-rearranged cholangiocarcinoma stopped early for poor accrual (48 of ~300): median PFS 7.4 vs 8.0 months; grade 3-4 adverse events 79.3% vs 58.8%; no definitive conclusions.
RCTn = 48
Abou-Alfa et al. Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301